Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29823338 | 1.00 | HTT (0.51) | HTTTSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL29823485 | 0.84 | TSHR (0.56) | HTTTSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL1875194 | 0.84 | TSHR (0.56) | HTTTSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL28448207 | 0.73 | HTT (0.46) | HTTTSHRKDM4ELMNAALDH1A1 | |
| SCHEMBL29823495 | 0.73 | CCR3 (0.45) | TSHRKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL1870607 | 0.73 | CCR3 (0.45) | TSHRKDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL22581108 | 0.71 | ALDH1A1 (0.41) | ALDH1A1KMT2ASMN1; SMN2MEN1NPC1 | |
| SCHEMBL1879911 | 0.70 | ALDH1A1 (0.39) | TSHRKDM4ELMNAALDH1A1KMT2A | |
| SCHEMBL29823258 | 0.70 | ALDH1A1 (0.43) | KDM4EALDH1A1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL1877208 | 0.70 | ALDH1A1 (0.43) | KDM4EALDH1A1KMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2371361-A1 | Methods to mobilize progenitor/stem cells | Genzyme Global S.à.r.l. (LU) | 2011-10-05 | — | — | EP | claimed |
| US-7935692-B2 | Methods to mobilize progenitor/stem cells | GENZYME CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2010-04-29 | — | — | US | claimed |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | GENZYME CORPORATION | 2010-02-11 | — | — | US | claimed |
| EP-1163238-B1 | CHEMOKINE RECPETOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2006-05-31 | — | — | EP | claimed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | claimed |
| US-6750348-B1 | PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE | ANORMED, INC. (CA) | 2004-06-15 | — | — | US | claimed |
| US-20250295698-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | ENSOMA INC (US) | 2025-09-25 | — | — | US | disclosed |
| US-20250032549-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | ENSOMA INC (US) | 2025-01-30 | — | — | US | disclosed |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | KEEFER, Edward (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240189387-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | ENSOMA, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-3735412-B1 | COMPOSITIONS AND METHODS FOR THE EXPANSION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS AND TREATMENT OF INHERITED METABOLIC DISORDERS | EDIGENE BIOTECHNOLOGY INC (CN) | 2024-02-21 | — | — | EP | disclosed |
| EP-4308694-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | Magenta Therapeutics, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20050043367-A1 | Methods to mobilize progenitor/stem cells | ANORMED CORPORATION (CA) | 2005-02-24 | — | — | US | disclosed |
| WO-2005000333-A1 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2005-01-06 | — | — | WO | disclosed |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2004-11-25 | — | — | US | disclosed |
| US-6750348-B1 | PROTECTIVE EFFECTS AGAINST INFECTION BY HIV THROUGH BINDING TO CHEMOKINE RECEPTORS, INCLUDING CXCR4 AND CCR5;N-(2-PYRIDINYLMETHYL)-N'-(2-(PHENYLUREIDO)ETHYL)-N'-(5,6,7,8-TETRAHYDRO-8-QUINOLINYL)-1,4-BENZENEDIMETHANAMINE | ANORMED, INC. (CA) | 2004-06-15 | — | — | US | disclosed |
| EP-1411918-A2 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2004-04-28 | — | — | EP | disclosed |
| US-20030130250-A1 | Methods to mobilize progenitor/stem cells | ANORMED, INC. (CA) | 2003-07-10 | — | — | US | disclosed |
| WO-2003011277-A2 | METHODS TO MOBILIZE PROGENITOR/STEM CELLS | ANORMED INC. (CA) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189387-A1 | DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS | CXCL12, MCL1, MYADM | HTT 1301/4885TSHR 4616/4885KDM4E 2556/4885 |
| US-20100105915-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CXCR4, CCR5, CXCR3 | HTT 4250/4885TSHR 2215/4885KDM4E 4575/4885 |
| US-20050043367-A1 | Methods to mobilize progenitor/stem cells | CXCL12, CXCR4, CXCR1 | HTT 3156/4885TSHR 2429/4885KDM4E 2301/4885 |
| US-20100035941-A1 | METHODS FOR INCREASING BLOOD FLOW AND/OR PROMOTING TISSUE REGENERATION | CCR2, CXCR4, CXCR2 | HTT 4519/4885TSHR 772/4885KDM4E 2151/4885 |
| US-20250032549-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS | CXCL12, CD44, CD47 | HTT 295/4885TSHR 3569/4885KDM4E 2938/4885 |
| US-20240285831-A1 | METHODS OF USE OF MODULATORS TO IMPROVE NERVE REGENERATION | CXCR3, CXCL12, CXCR4 | HTT 4811/4885TSHR 1710/4885KDM4E 3304/4885 |
| US-20030130250-A1 | Methods to mobilize progenitor/stem cells | CXCR4, CXCL12, CXCR2 | HTT 3626/4885TSHR 1823/4885KDM4E 2485/4885 |
| US-20250295698-A1 | DOSING REGIMENS FOR THE MOBILIZATION OF HEMATOPOIETIC STEM CELLS | CXCL12, CSF3R, THPO | HTT 625/4885TSHR 2725/4885KDM4E 4210/4885 |
| US-20040235823-A1 | Chemokine receptor binding heterocyclic compounds | CCR5, CXCR4, CXCR1 | HTT 4705/4885TSHR 1535/4885KDM4E 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.